vimarsana.com

Page 143 - கண் இமை மயிர்களுக்கு ஊட்டப்படும் ஒரு வகை சாய கலவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Anne McGeorge, Former Managing Partner of Grant Thornton LLP, Joins CitiusTech s Board of Directors and Chair of the Audit Committee

[January 12, 2021] Anne McGeorge, Former Managing Partner of Grant Thornton LLP, Joins CitiusTech s Board of Directors and Chair of the Audit Committee CitiusTech, a leading provider of healthcare technology services and solutions, announced today that Anne McGeorge, former Managing Partner of Grant Thornton s (News - Alert) Global Health Care and Life Sciences Practices, has joined its Board of Directors and chair of the Audit Committee. Ms. McGeorge comes with over 35 years of experience advising healthcare clients in all aspects of finance and transformational change, including strategy, M&A, joint ventures, financial statement audits, corporate restructuring, governance, talent acquisition, executive compensation, IRS matters and risk management. She created the healthcare / life sciences practice for Grant Thornton and grew it to a $250 million global business in a little over 10 years. Prior to spending over 11 years at Grant Thornton, Ms. McGeorge was a Partner at Deloitt

Massachusetts expands role of optometrists in glaucoma treatment | NECO Mag

January 12, 2021 Telemedicine coverage by insurance also covered in new law The first day of 2021 rang in good news for optometrists in Massachusetts. A multi-faceted healthcare bill was signed into law that allows optometrists to prescribe topical medications for the treatment of glaucoma and to have authority to prescribe oral anti-infectives, moving the state in line with common optometric practice across the rest of the country. New England College of Optometry (NECO) along with many organizations, optometrists and students actively advocated for this important change.  “At NECO, our faculty attendings are trained to diagnose, monitor, and treat glaucoma and to teach our students to practice in any state. However in Massachusetts, optometrists were withheld from prescribing glaucoma drops, the most common treatment,” notes Gary Chu, OD, MPH, VP of Professional  Affairs. 

Daily Reading for Tuesday, January 12th, 2021 - Bible

The daily readings are taken from the lectionary which divides much of the Bible into three years worth of readings. If you complete the daily readings each day for three years, you will read 15 percent of the Old Testament and 71 percent of the New Testament.

Top judokas eye Olympic berths in Doha

Top judokas eye Olympic berths in Doha  11 Jan 2021 - 9:02 The Peninsula Doha: Since the resumption of the World Judo Tour at Grand Slam Hungary, last October, the judo world had been eagerly waiting for the launch of the new season. With the Doha World Judo Masters which begins today, this has been made possible, thanks to Qatar. The draw for Doha World Judo Masters – the 2020 Tokyo Olympics qualifying event took place at the Lusail Multipurpose Hall yesterday. With tight regulations in place as per the Ministry of Public Health guidelines, the Qatar Judo & Taekwondo Federation and the International Judo Federation have ensured a much looked forward to event. IJF President Marius Vizer thanked The Amir H H Sheikh Tamim bin Hamad Al Thani during his welcome speech on the occasion of the draw, which was held entirely online.

Firepower 2021: life sciences M&A falls to one of lowest totals since 2014, as biopharmas refocus on alliances and bolt-on deals

Share this article Share this article NEW YORK, Jan. 11, 2021 /PRNewswire/ Life sciences mergers and acquisitions (M&A) activity totaled US$159b in 2020, down from US$306b in 2019, reaching one of the lowest levels since 2014, according to the 2021 EY , launched today. A single megadeal – AstraZeneca s December purchase of Alexion Pharmaceuticals – accounted for a quarter of the annual life sciences M&A spend. Setting aside the challenges of doing diligence and closing deals virtually due to the COVID-19 pandemic, persistently high valuations for biopharma and medtech targets kept many would-be buyers on the sidelines, in what was already expected to be a difficult year. In this unfavorable environment, biopharma acquirers refocused their energy on alliances and smaller, bolt-on deals in high-priority therapeutic areas. Medtechs experienced revenue slowdowns due to the cancellation or deferment of procedures in 2020.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.